Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | CTSD | P07339 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 11/20 | 0.36 |
| ▸ | EP300 | Q09472 | 1/20 | 0.34 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL231542 | 0.75 | MAPT (0.47) | — | |
| SCHEMBL2458142 | 0.73 | HDAC3 (0.41) | SLC6A2 | |
| SCHEMBL234584 | 0.67 | ATM (0.39) | CNR1BACE1P2RX7 | |
| SCHEMBL733566 | 0.66 | — | — | |
| SCHEMBL11393319 | 0.66 | HDAC3 (0.48) | — | |
| SCHEMBL24330498 | 0.65 | RRM2 (0.42) | — | |
| SCHEMBL230230 | 0.64 | KDM4E (0.38) | — | |
| SCHEMBL3406637 | 0.64 | SLC6A4 (0.47) | CNR1SLC6A4SLC6A3SLC6A2P2RX7 | |
| SCHEMBL4005376 | 0.64 | LTA4H (0.43) | — | |
| SCHEMBL11393082 | 0.62 | P4HTM (0.58) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2406220-A1 | BIS AROMATIC COMPOUNDS FOR USE AS LTC4 SYNTHASE INHIBITORS | Biolipox AB (SE) | 2012-01-18 | — | — | EP | disclosed |
| US-20120004228-A1 | Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors | BIOLIPOX AB (SW) | 2012-01-05 | — | — | US | disclosed |
| WO-2010103279-A1 | BIS AROMATIC COMPOUNDS FOR USE AS LCT4 SYNTHASE INHIBITORS | BIOLIPOX AB (SE) | 2010-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004228-A1 | Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors | LTC4S, LTB4R2, LTB4R | CNR1 509/4885SLC6A4 2522/4885SLC6A3 2118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.